Eric Carter - Alder BioPharmaceutica Interim Chief Medical Officer
Executive
Dr. Eric G. Carter, M.D., Ph.D., is Interim Chief Medical Officer of the Company. Dr. Carter served as Senior Vice President, Chief Medical Officer and Global Head of Clinical NonClinical Development of Allergan Inc. from 2011 to 2015, where he led the organization through 11 domestic and international drug candidate approvals and managed an annual budget of approximately 700 million. With more than 20 years of experience as a physician and as an executive in the pharmaceutical industry, Dr. Carter has overseen the introduction of new drug candidates into clinical development and practice, managed complex processes and global teams and provided support around key commercialization activities for numerous organizations. Dr. Carter currently serves as Chairman of the Scientific Advisory Board of Bioniz Therapeutics, a clinicalstage biopharmaceutical company, and serves on the Board of Directors of Adverum Biotechnologies, a public gene therapy company focused on rare diseases since 2018.
| Age | 64 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Phone | 425 205-2900 |
| Web | www.alderbio.com |
Alder BioPharmaceutica Management Efficiency
The company has return on total asset (ROA) of (100.8551) % which means that it has lost $100.8551 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4193) %, meaning that it created substantial loss on money invested by shareholders. Alder BioPharmaceutica's management efficiency ratios could be used to measure how well Alder BioPharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 193.36 M in liabilities with Debt to Equity (D/E) ratio of 89.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Alder BioPharmaceuticals has a current ratio of 8.76, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Alder BioPharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Alder BioPharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Alder BioPharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Alder to invest in growth at high rates of return. When we think about Alder BioPharmaceutica's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Joseph Piantedosi | Park Hotels Resorts | N/A | |
| Michael Conway | Starbucks | 57 | |
| Rebecca Flemming | Park Hotels Resorts | N/A | |
| Brandon Satoren | Logan Ridge Finance | 35 | |
| Andy Adams | Starbucks | N/A | |
| Gregory CPA | Artisan Partners Asset | 53 | |
| Brady Brewer | Starbucks | 51 | |
| Bruce Lewis | Biglari Holdings | 59 | |
| Darren Robb | Park Hotels Resorts | 47 | |
| Ian Weissman | Park Hotels Resorts | N/A | |
| Tiffany Willis | Starbucks | N/A | |
| Scott Winer | Park Hotels Resorts | N/A | |
| Emmy Kan | Starbucks | N/A | |
| Adam Wudel | Summit Hotel Properties | N/A | |
| Bryan CFA | Artisan Partners Asset | N/A | |
| Sara Kelly | Starbucks | 44 | |
| Paul CPA | Summit Hotel Properties | 57 | |
| Jonathan Fuisz | Park Hotels Resorts | N/A | |
| Aranthan II | Starbucks | 47 | |
| David Strow | Boyd Gaming | N/A | |
| Michael McKinnon | Artisan Partners Asset | N/A | |
Management Performance
| Return On Equity | -1.42 | |||
| Return On Asset | -100.86 |
Alder BioPharmaceuticals Leadership Team
Elected by the shareholders, the Alder BioPharmaceutica's board of directors comprises two types of representatives: Alder BioPharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alder. The board's role is to monitor Alder BioPharmaceutica's management team and ensure that shareholders' interests are well served. Alder BioPharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alder BioPharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erin Lavelle, COO | ||
| Xavier GallotLavallee, Member of the Supervisory Board | ||
| Deepa Pakianathan, Independent Director | ||
| Bruce Montgomery, Independent Director | ||
| Paul Streck, Chief Medical Officer | ||
| Anne TrotouxCoppermann, Member of the Supervisory Board | ||
| Robert Azelby, President CEO | ||
| Christian Viguie, Chairman of the Supervisory Board | ||
| Deepika Pakianathan, Independent Director | ||
| John Latham, Co-Founder and Chief Scientific Officer | ||
| Jeremy Green, Director | ||
| Bruno Pavlovsky, Member of the Supervisory Board | ||
| Wendy Yarno, Independent Director | ||
| Joel Desmaris, Member of the Management Board in Charge of Finance and Investor Relations | ||
| Olivier Lambert, Member of the Supervisory Board | ||
| Randal Hassler, Senior Vice President Pharmaceutical Operations | ||
| Paul Carter, Director | ||
| Stephen Dow, Independent Chairman of the Board | ||
| Randall Schatzman, Co-Founder, CEO and President and Director | ||
| Eric Carter, Interim Chief Medical Officer | ||
| Nadia Dac, Chief Commercial Officer | ||
| Mark Litton, Chief Business Officer, Treasurer and Secretary | ||
| Larry Benedict, Sr. VP of Fin. | ||
| Carlos Campoy, CFO | ||
| Pierre Conte, Member of the Supervisory Board | ||
| Pierre Tourrette, Vice Chairman of the Supervisory Board | ||
| Heather Preston, Independent Director | ||
| Jeffrey Smith, Senior Vice President Translational Medicine | ||
| Timothy Whitaker, Chief Medical Officer | ||
| James Bucher, Senior Vice President General Counsel | ||
| Paul Cleveland, Director | ||
| Clay Siegall, Independent Director | ||
| Frederic Serre, Chairman of the Management Board | ||
| Elisabeth Sandoval, Chief Commercial Officer | ||
| Philippe Mattia, Member of the Supervisory Board |
Alder Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alder BioPharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.42 | |||
| Return On Asset | -100.86 | |||
| Profit Margin | 15.82 % | |||
| Operating Margin | (7.69) % | |||
| Current Valuation | 1.46 B | |||
| Shares Outstanding | 83.64 M | |||
| Shares Owned By Insiders | 5.20 % | |||
| Shares Owned By Institutions | 94.80 % | |||
| Number Of Shares Shorted | 12.05 M | |||
| Price To Earning | (2.18) X |
Pair Trading with Alder BioPharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alder BioPharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alder BioPharmaceutica will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Deere could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Deere when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Deere - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Deere Company to buy it.
The correlation of Deere is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Deere moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Deere Company moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Deere can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Alder BioPharmaceuticals information on this page should be used as a complementary analysis to other Alder BioPharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Alder Stock
If you are still planning to invest in Alder BioPharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alder BioPharmaceutica's history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |